title: [Attractiveness of France for international clinical trials in 2012: 6(th) survey assessed by Leem (French association of pharmaceutical companies)].
abstract: Since 2002, the Leem (French Association of Pharmaceutical Companies) has conducted a survey every two years to update the attractiveness of France for international clinical trials. Thirty companies (68% of the French market) have participated in this 6(th) survey which involved 79 countries, a greater number of Phases I/II, II and III studies (420 versus 352 in 2010), a relatively stable number of included patients (246,895 versus 249,704 in 2010) and a greater number of centers (32,965 versus 24,337 in 2010). The evolution of time-lines for the go-ahead by French Authorities is heterogeneous (shorter time-lines by the French National Agency of Drug and Health Products Safety [ANSM] but longer time-lines by Research Ethics Comittees [CPP]). The time-lines for first hospital contracts remain stable. France ranks at an average position among European countries in regards to quantitative and qualitative data, and its state-of-art in early stages is still recognized. Its good performance in oncology and orphan diseases are major assets of competitiveness.
authors.affiliation: Les entreprises du médicament (Leem), Paris, France.
authors.forename: Catherine
authors.initials: C
authors.lastname: Lassale
authors.forename: Claire
authors.initials: C
authors.lastname: Sibenaler
authors.forename: Jehan-Michel
authors.initials: JM
authors.lastname: Béhier
authors.forename: Philippe
authors.initials: P
authors.lastname: Barthélémy
authors.forename: Yannick
authors.initials: Y
authors.lastname: Plétan
authors.forename: Soizic
authors.initials: S
authors.lastname: Courcier
mesh_terms: D017321:Clinical Trials, Phase I as Topic / Q000706:statistics & numerical data*; D017322:Clinical Trials, Phase II as Topic / Q000706:statistics & numerical data*; D017326:Clinical Trials, Phase III as Topic / Q000706:statistics & numerical data*; D003625:Data Collection; D004345:Drug Industry / Q000706:statistics & numerical data*; D005060:Europe; D005602:France; D006801:Humans; D007391:International Cooperation; D008495:Medical Oncology / Q000706:statistics & numerical data; D009965:Orphan Drug Production / Q000706:statistics & numerical data; D013997:Time Factors